Article

Laser system gets 510(k) clearance

The FDA granted 510(k) clearance March 16 to a laser system (LensAR Laser System, LensAR Inc.) for anterior capsulotomy and lens fragmentation during cataract surgery.

Silver Spring, MD-The FDA granted 510(k) clearance March 16 to a laser system (LensAR Laser System, LensAR Inc.) for anterior capsulotomy and lens fragmentation during cataract surgery.

“Receiving the additional FDA indication for lens fragmentation is a significant milestone achievement in getting our technology one step closer to commercialization,” said Randy Frey, founder and chief executive officer of LensAR.

The system includes a proprietary imaging and biometry system (3-D CSI, which stands for three-dimensional confocal structured illumination) for imaging and analysis of the anatomy across all grades of cataract, to improve proficiency. The imaging and biometry system is designed to provide clean, low-noise images that are both high contrast and high resolution from the anterior surface of the cornea to the posterior capsule. The laser’s precision helps with capsulotomy incision size and placement based on IOL selection and fragments high-grade cataracts for easier removal, according to the company.

The system has been used in more than 500 eyes outside the United States to date. For indications other than anterior capsulotomy and lens fragmentation during cataract surgery in the United States, the system is an investigational device.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.